We now know from the announcement of 19 June 2017, that Dr Robert Hayes, formerly the Head of Centyrex and VP of Janssen, was instrumental in the progression of the Janssen collaboration to use phylomers for the intracellular delivery of a designated payload. Back in late 2013, however, the detail around the collaboration was the subject of fierce speculation which has subsequently turned out to be well informed.
BEN_1312, a virulence factor in cell invasion, was favoured by a number of posters as the phylomer most likely. It appears the past has caught up with the present due to the Benefactor.
A Star in the Making, page-17
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.005(2.70%) |
Mkt cap ! $886.5M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 19.0¢ | 17.5¢ | $508.8K | 2.763M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 118941 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 183634 | 2 |
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| PYC (ASX) Chart |
Day chart unavailable